ClinicalTrials.gg
RecruitingNCT07695142Updated Oct 27, 2026

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HSK46256 in Advanced Solid Tumor (Phase 1), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 27, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
275
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors. The study consists of a dose escalation phase and a dose expansion phase. In the dose escalation phase, a 3+3 dose escalation design will be used to evaluate multiple dose levels. The dose expansion phase will enroll patients into expansion cohorts at selected dose levels to further evaluate safety and preliminary efficacy.

02

Conditions studied

  • Advanced Solid Tumor (Phase 1)

Keywords

  • PARP inhibitor
  • advanced solid tumors
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years, voluntarily participate and provide signed ,
  • performance status 0-1 or >60; estimated ≥12 weeks,
  • or cytologically confirmed locally advanced or solid tumors, failed prior standard therapy, intolerant to standard therapy, or no available standard therapy,
  • Dose escalation: prior treatment with one line of non-selective PARP inhibitor allowed,
  • Documented HRR gene mutation,
  • Agree to provide tumor tissue and/or blood samples,
  • Fertile participants must agree to use effective during study and for 3 months after last dose; negative pregnancy test for females,

Exclusion criteria

Exclusion Criteria:

  • Other within past 2 years (except adequately treated basal cell carcinoma, squamous cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma);
  • Uncontrolled moderate to large pleural, pericardial, or peritoneal effusions;
  • Prior anticancer therapy or concomitant use of strong/moderate inhibitors/inducers within protocol-specified ;
  • Prior anticancer treatment toxicity not resolved to ≤Grade 1 (except alopecia, skin toxicity);
  • Any condition affecting drug swallowing or significantly impacting drug absorption/PK;
  • Severe or uncontrolled cardiac disease ( prolongation, significant arrhythmia, \<50%, recent MI/heart failure);
  • Arterial/venous thromboembolic events within 6 months deemed uncontrolled risk;
  • Severe/uncontrolled diabetes, hypertension, active bleeding, epilepsy, , interstitial lung disease, active systemic infection;
  • Unstable systemic disease (severe hepatic/renal/metabolic disorders);
  • Prior MDS or AML diagnosis, or history of hematopoietic stem cell transplantation;
  • Major surgery or severe trauma within 4 weeks;
  • positive, active /C, or active syphilis;
  • Known to study drug or ;
  • Participation in another interventional trial within 4 weeks;
  • Pregnant or lactating women;
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Experimental
    HSK46256 as monotherapy

    Drug: HSK46256 Administration: Oral tablet, once daily (except during the single-dose period) Regimen: Single-agent, dose-escalation Duration: Until disease progression or treatment discontinuation

    Drug: HSK46256

Interventions

  • DrugHSK46256

    Oral administration. Dose escalation: an initial single-dose period followed by multiple-dose cycles until disease progression or intolerable toxicity. Dose expansion: multiple-dose cycles directly. Specific dose levels and dosing frequency will be determined based on dose-escalation data.

06

What researchers measure

Primary outcomes

  1. DLTs

    Incidence of dose-limiting toxicities (DLTs) at Cycle1

    Time frame: Up to 24 days

  2. MTD

    Maximum Tolerated Dose

    Time frame: Up to 24 days

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: Up to 24 months

  2. Duration of Response (DOR)

    Time frame: Up to 24 months

  3. Disease Control Rate (DCR)

    Time frame: Up to 24 months

  4. Radiographic Progression-Free Survival (rPFS, prostate cancer only)

    Time frame: Up to 24 months

  5. Objective Response Rate (ORR)

    Complete response + Partial response (CR+PR) based on RECIST 1.1.

    Time frame: Up to 24 months

  6. PK parameters of HSK46256

    Peak plasma concentration (Cmax)

    Time frame: Circle 1 (21 days)

  7. Pharmacokinetic parameters of HSK46256

    Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: Circle 1 (21 days)

  8. Pharmacokinetic parameters of HSK46256

    Half-life (T1/2)

    Time frame: Circle 1 (21 days)

Other outcomes

  1. Pharmacodynamic (PD) markers: PARP1 inhibition and biomarker modulation

    Time frame: Circle 1 (21 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 10, 2026
StartActual
Aug 7, 2026was Jul 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
Fudan University Shanghai Cancer Center is now Recruiting
Oct 27, 2026
Start date
Jul 9, 2026→Aug 7, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    Fudan University Shanghai Cancer Center is now Recruiting
    Start date Jul 9, 2026→Aug 7, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695142
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Aug 7, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion